Breaking News Instant updates and real-time market news.

13:35
10/06/20
10/06
13:35
10/06/20
13:35

Treasury's $34 B B 52-week bill sale was well sponsored

Treasury's $34 B B 52-week bill sale was well sponsored, likely getting something of a have bid. The bill cleared at 0.140%, right on the screws. And this is an all-time rich award rate, tying the rates from September and August as well. There were nearly $107 B in bids for a 3.15 cover, better than the 3.04 last month but little changed from the 3.14 average. Indirect bidders took 41.7%, stronger than the 30.4% previously, as well as the 36.6% average.

TODAY'S FREE FLY STORIES

Hot Stocks
Fly Intel: Top five weekend stock stories » 19:56
10/25/20
10/25
19:56
10/25/20
19:56
DNKN

Dunkin' Brands

$88.70 /

-0.5 (-0.56%)

, BX

Blackstone

$54.59 /

-0.17 (-0.31%)

, BAM

Brookfield

$33.89 /

+0.025 (+0.07%)

, SFM

Sprouts Farmers Market

$20.67 /

-0.17 (-0.82%)

, TGT

Target

$160.25 /

+0.625 (+0.39%)

, WMT

Walmart

$143.86 /

+0.33 (+0.23%)

, CCEP

Coca-Cola European Partners

$39.00 /

-0.485 (-1.23%)

, CCLAY

Coca-Cola Amatil

$0.00 /

+ (+0.00%)

, KO

Coca-Cola

$50.52 /

-0.15 (-0.30%)

, NEE

NextEra Energy

$303.15 /

+0.925 (+0.31%)

, XEL

Xcel Energy

$71.44 /

+0.05 (+0.07%)

, WEC

WEC Energy

$102.12 /

+0.46 (+0.45%)

, ES

Eversource

$91.93 /

-0.99 (-1.07%)

, CMS

CMS Energy

$65.83 /

+0.09 (+0.14%)

, LNT

Alliant Energy

$56.71 /

+0.26 (+0.46%)

, ATO

Atmos Energy

$97.67 /

+0.97 (+1.00%)

, NJR

New Jersey Resources

$29.54 /

+0.14 (+0.48%)

Catch up on the…

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Dunkin' Brands (DNKN), the parent company of Dunkin' and Baskin-Robbins, confirmed that it has held preliminary discussions to be acquired by Inspire Brands. There is no certainty that any agreement will be reached. The company said it will not comment further unless and until a transaction is agreed or discussions are terminated. This follows a news report by the New York Times's Lauren Hirsch saying that Dunkin' Brands was in talks to sell itself to Inspire Brands, in a deal that would take Dunkin' Brands private at a price of $106.50 a share. 2. Blackstone (BX) has struck a deal to buy Simply Self Storage from Brookfield Asset Management (BAM), The Wall Street Journal's Miriam Gottfried reports. The private-equity company's nontraded real-estate investment trust, known as BREIT, is buying the 8M square-foot portfolio of self-storage facilities for about $1.2B. The deal is expected to be announced Monday, the author adds. 3. Sprouts Farmers Market (SFM) was a COVID-19 winner, and then it was a COVID-19 loser, but its earnings report on October 28 could make it a winner again, Teresa Rivas wrote in this week's edition of Barron's. After peaking in the March quarter, Sprouts' same-store sales declined as consumers favored one-stop-shops like Target (TGT) and Walmart (WMT) to reduce the risk of virus exposure, the author noted, adding that its stock has dropped 22% in the past three months. However, Sprouts' earnings could help the stock reverse course, the publication contended. 4. Coca-Cola European Partners (CCEP) announced it has made a non-binding proposal to acquire Coca-Cola Amatil (CCLAY). The Board of Directors of CCEP has made a non-binding offer to acquire 69.2% of the entire existing issued share capital of Coca-Cola Amatil, which is held by shareholders other than Coca-Cola, to be effected by means of a scheme of arrangement; and has entered into a non-binding heads of terms and cooperation letter with Coca-Cola (KO), setting out the terms on which Coca-Cola European Partners proposes to acquire Coca-Cola's 30.8% interest in Coca-Cola Amatil, conditional upon Australian regulatory approvals and the implementation of the scheme of arrangement. Coca-Cola Amatil's Independent Shareholders would receive A$12.75 per share in cash. Coca-Cola would receive A$9.57 per share in cash for part of their shareholding, which comprises 10.8% of Coca-Cola Amatil's shares. Coca-Cola European Partners will work with Coca-Cola to acquire all of Coca-Cola's remaining 20% shareholding in Coca-Cola Amatil, in connection with which Coca-Cola European Partners may satisfy part of the consideration for these Coca-Cola Amatil shares by the issue of Coca-Cola European Partners shares at an agreed conversion ratio. 5. Coca-Cola, NextEra Energy (NEE), Xcel Energy (XEL), WEC Energy (WEC), Eversource Energy (ES), CMS Energy (CMS), Alliant Energy (LNT), Atmos Energy (ATO), and New Jersey Resources (NJR) saw positive mentions in this week's edition of Barron's.

ShowHide Related Items >><<
XEL Xcel Energy
$71.44 /

+0.05 (+0.07%)

WMT Walmart
$143.86 /

+0.33 (+0.23%)

WEC WEC Energy
$102.12 /

+0.46 (+0.45%)

TGT Target
$160.25 /

+0.625 (+0.39%)

SFM Sprouts Farmers Market
$20.67 /

-0.17 (-0.82%)

NJR New Jersey Resources
$29.54 /

+0.14 (+0.48%)

NEE NextEra Energy
$303.15 /

+0.925 (+0.31%)

LNT Alliant Energy
$56.71 /

+0.26 (+0.46%)

KO Coca-Cola
$50.52 /

-0.15 (-0.30%)

DNKN Dunkin' Brands
$88.70 /

-0.5 (-0.56%)

CMS CMS Energy
$65.83 /

+0.09 (+0.14%)

CCEP Coca-Cola European Partners
$39.00 /

-0.485 (-1.23%)

BX Blackstone
$54.59 /

-0.17 (-0.31%)

BAM Brookfield
$33.89 /

+0.025 (+0.07%)

DNKN Dunkin' Brands
$88.70 /

-0.5 (-0.56%)

10/23/20 KeyBanc
Dunkin' Brands price target raised to $97 from $78 at KeyBanc
10/20/20 Cleveland Research
Dunkin' Brands U.S. comps look to have improved, says Cleveland Research
10/19/20 Wells Fargo
Dunkin' Brands price target raised to $83 from $67 at Wells Fargo
10/06/20 Piper Sandler
Piper teen survey shows Snap, Amazon and Apple remain favorites
BX Blackstone
$54.59 /

-0.17 (-0.31%)

06/25/20
Fly Intel: Top five analyst initiations
06/25/20 UBS
Blackstone initiated with a Buy at UBS
06/08/20 Citi
Citi downgrades Alternative Asset Managers to Market Weight, lowers four ratings
06/08/20 Citi
Blackstone downgraded to Neutral from Buy at Citi
BAM Brookfield
$33.89 /

+0.025 (+0.07%)

10/23/20 Credit Suisse
Athene could still bid for American Equity, faces 'hurdles,' says Credit Suisse
10/19/20
Fly Intel: Top five analyst upgrades
10/19/20 Citi
Brookfield upgraded to Buy from Neutral at Citi
09/23/20 JPMorgan
Brookfield shares remain undervalued, says JPMorgan
SFM Sprouts Farmers Market
$20.67 /

-0.17 (-0.82%)

10/20/20
Fly Intel: Top five analyst downgrades
10/20/20 Gordon Haskett
Sprouts Farmers Market downgraded to Hold from Buy at Gordon Haskett
08/06/20 Credit Suisse
Sprouts Farmers Market assumed with a Neutral at Credit Suisse
07/30/20
Fly Intel: Top five analyst initiations
TGT Target
$160.25 /

+0.625 (+0.39%)

10/23/20 Evercore ISI
Kroger downgraded to In Line from Outperform at Evercore ISI
10/15/20 Jefferies
Target assumed with a Hold at Jefferies
10/08/20 Deutsche Bank
Deutsche Bank initiates 'Catalyst Call: Buy Idea' on Target
09/22/20 Cleveland Research
Target sales appear to be re-accelerating, says Cleveland Research
WMT Walmart
$143.86 /

+0.33 (+0.23%)

10/20/20 Stephens
Keeping Sam's Club a 'nice win' for Synchrony, says Stephens
10/15/20 Jefferies
Walmart assumed with a Buy at Jefferies
10/13/20 Bernstein
Bernstein downgrades Beyond Meat to Underperform on 'stretched' valuation
CCEP Coca-Cola European Partners
$39.00 /

-0.485 (-1.23%)

07/06/20 ABN Amro
Coca-Cola European Partners upgraded to Buy from Hold at ABN Amro
06/22/20 Citi
Citi calls Coca-Cola European Partners its Top Pick in Beverages
06/10/20 ABN Amro
Coca-Cola European Partners upgraded to Hold from Sell at ABN Amro
06/05/20 HSBC
Coca-Cola European Partners initiated with a Hold at HSBC
CCLAY Coca-Cola Amatil
$0.00 /

+ (+0.00%)

10/21/20 JPMorgan
Coca-Cola Amatil upgraded to Overweight from Neutral at JPMorgan
08/06/20 Goldman Sachs
Coca-Cola Amatil upgraded to Buy from Neutral at Goldman Sachs
05/26/20 Goldman Sachs
Coca-Cola Amatil upgraded to Neutral from Sell at Goldman Sachs
05/26/20 Goldman Sachs
Coca-Cola Amatil upgraded to Neutral from Sell at Goldman Sachs
KO Coca-Cola
$50.52 /

-0.15 (-0.30%)

10/23/20 Morgan Stanley
Coca-Cola price target raised to $57 from $54 at Morgan Stanley
10/20/20 Jefferies
National Beverage upgraded to Hold on better La Croix market share at Jefferies
10/12/20 Citi
PepsiCo upgraded to Buy from Neutral at Citi
09/28/20 Morgan Stanley
PepsiCo trading at good entry point ahead of earnings, says Morgan Stanley
NEE NextEra Energy
$303.15 /

+0.925 (+0.31%)

10/19/20 Credit Suisse
NextEra Energy price target raised to $305 from $266 at Credit Suisse
09/30/20 JPMorgan
NextEra deal for Duke may be possible, but would come with risks, says JPMorgan
09/22/20 JPMorgan
NextEra Energy price target raised to $297 from $289 at JPMorgan
09/22/20 Seaport Global
Seaport starts 'hard to resist' NextEra Energy with Buy, $229 target
XEL Xcel Energy
$71.44 /

+0.05 (+0.07%)

08/25/20
Fly Intel: Top five analyst downgrades
08/25/20 Argus
Xcel Energy downgraded to Hold from Buy at Argus
08/25/20 Argus
Xcel Energy downgraded to Hold from Buy at Argus
08/21/20 Mizuho
Xcel Energy price target raised to $68 from $61 at Mizuho
WEC WEC Energy
$102.12 /

+0.46 (+0.45%)

09/15/20 Argus
WEC Energy price target raised to $105 from $100 at Argus
09/04/20 Atlantic Equities
WEC Energy initiated with an Overweight at Atlantic Equities
04/24/20 Wells Fargo
WEC Energy downgraded to Equal Weight at Wells Fargo on relative valuation
04/24/20 Wells Fargo
WEC Energy downgraded to Equal Weight from Overweight at Wells Fargo
ES Eversource
$91.93 /

-0.99 (-1.07%)

10/05/20 BofA
Eversource upgraded to Neutral from Underperform at BofA
10/05/20 BofA
Eversource upgraded to Buy from Neutral at BofA
08/24/20
Fly Intel: Top five analyst downgrades
08/24/20 Guggenheim
Guggenheim cuts Eversource to Neutral, prefers Dominion as offshore wind play
CMS CMS Energy
$65.83 /

+0.09 (+0.14%)

10/23/20 Mizuho
CMS Energy price target raised to $67 from $61 at Mizuho
09/21/20 Barclays
CMS Energy downgraded to Equal Weight from Overweight at Barclays
07/09/20 BMO Capital
CMS Energy initiated with an Outperform at BMO Capital
05/20/20 Seaport Global
Seaport Global starts CMS Energy at Buy with $61.50 price target
LNT Alliant Energy
$56.71 /

+0.26 (+0.46%)

10/12/20 Mizuho
Alliant Energy price target raised to $53 from $51 at Mizuho
09/21/20 Barclays
Alliant Energy downgraded to Equal Weight from Overweight at Barclays
08/10/20 Wells Fargo
Alliant Energy price target raised to $62 from $55 at Wells Fargo
03/16/20 Guggenheim
Alliant Energy upgraded to Buy from Neutral at Guggenheim
ATO Atmos Energy
$97.67 /

+0.97 (+1.00%)

09/25/20 Mizuho
Atmos Energy price target lowered to $99 from $110 at Mizuho
07/13/20 Seaport Global
Atmos Energy initiated with a Buy at Seaport Global
06/05/20 Mizuho
Atmos Energy price target lowered to $110 from $118 at Mizuho
04/01/20 UBS
Atmos Energy upgraded to Buy from Neutral at UBS
NJR New Jersey Resources
$29.54 /

+0.14 (+0.48%)

07/24/20
Fly Intel: Top five analyst initiations
07/23/20 Mizuho
New Jersey Resources initiated with a Buy at Mizuho
04/23/20 BofA
New Jersey Resources reinstated with an Underperform at BofA
04/23/20 BofA
New Jersey Resources reinstated with an Underperform at BofA
XEL Xcel Energy
$71.44 /

+0.05 (+0.07%)

WMT Walmart
$143.86 /

+0.33 (+0.23%)

WEC WEC Energy
$102.12 /

+0.46 (+0.45%)

TGT Target
$160.25 /

+0.625 (+0.39%)

SFM Sprouts Farmers Market
$20.67 /

-0.17 (-0.82%)

NJR New Jersey Resources
$29.54 /

+0.14 (+0.48%)

NEE NextEra Energy
$303.15 /

+0.925 (+0.31%)

LNT Alliant Energy
$56.71 /

+0.26 (+0.46%)

KO Coca-Cola
$50.52 /

-0.15 (-0.30%)

ES Eversource
$91.93 /

-0.99 (-1.07%)

DNKN Dunkin' Brands
$88.70 /

-0.5 (-0.56%)

CMS CMS Energy
$65.83 /

+0.09 (+0.14%)

BX Blackstone
$54.59 /

-0.17 (-0.31%)

BAM Brookfield
$33.89 /

+0.025 (+0.07%)

ATO Atmos Energy
$97.67 /

+0.97 (+1.00%)

  • 11
    Jun
  • 05
    Dec
  • 14
    Nov
  • 31
    Oct
WMT Walmart
$143.86 /

+0.33 (+0.23%)

WEC WEC Energy
$102.12 /

+0.46 (+0.45%)

TGT Target
$160.25 /

+0.625 (+0.39%)

SFM Sprouts Farmers Market
$20.67 /

-0.17 (-0.82%)

NEE NextEra Energy
$303.15 /

+0.925 (+0.31%)

KO Coca-Cola
$50.52 /

-0.15 (-0.30%)

DNKN Dunkin' Brands
$88.70 /

-0.5 (-0.56%)

CCEP Coca-Cola European Partners
$39.00 /

-0.485 (-1.23%)

BX Blackstone
$54.59 /

-0.17 (-0.31%)

BAM Brookfield
$33.89 /

+0.025 (+0.07%)

WMT Walmart
$143.86 /

+0.33 (+0.23%)

TGT Target
$160.25 /

+0.625 (+0.39%)

SFM Sprouts Farmers Market
$20.67 /

-0.17 (-0.82%)

NEE NextEra Energy
$303.15 /

+0.925 (+0.31%)

KO Coca-Cola
$50.52 /

-0.15 (-0.30%)

DNKN Dunkin' Brands
$88.70 /

-0.5 (-0.56%)

BX Blackstone
$54.59 /

-0.17 (-0.31%)

BAM Brookfield
$33.89 /

+0.025 (+0.07%)

WMT Walmart
$143.86 /

+0.33 (+0.23%)

TGT Target
$160.25 /

+0.625 (+0.39%)

SFM Sprouts Farmers Market
$20.67 /

-0.17 (-0.82%)

NEE NextEra Energy
$303.15 /

+0.925 (+0.31%)

KO Coca-Cola
$50.52 /

-0.15 (-0.30%)

BX Blackstone
$54.59 /

-0.17 (-0.31%)

Recommendations
Turning Point Therapeutics price target raised to $120 from $90 at Oppenheimer » 19:48
10/25/20
10/25
19:48
10/25/20
19:48
TPTX

Turning Point Therapeutics

$102.72 /

+0.82 (+0.80%)

Oppenheimer analyst…

Oppenheimer analyst Matthew Biegler raised the firm's price target on Turning Point Therapeutics to $120 from $90 and keeps an Outperform rating on the shares. The analyst notes that Turning Point has unveiled initial data for TPX-0022 in a late-breaker at the virtual EORTC-NCI-AACR Meeting. The results were "amongst the most impressive" he has seen for any MET inhibitor-showing clear signs of activity in a variety of Exon14del and MET-amplified genotypes. Biegler believes the clinical profile of TPX-0022 could open the door for accelerated paths to market. The analyst notes that other MET inhibitors are currently only approved for Exon14del lung cancer, and MET was flagged as the target most in need of better drugs in his recent prescriber survey. Based on these data, Biegler is also increasing his Probability of Success for the program to 35% from 15%.

ShowHide Related Items >><<
TPTX Turning Point Therapeutics
$102.72 /

+0.82 (+0.80%)

TPTX Turning Point Therapeutics
$102.72 /

+0.82 (+0.80%)

09/21/20 H.C. Wainwright
Turning Point price target raised to $100 from $88 at H.C. Wainwright
08/21/20 Canaccord
Turning Point Therapeutics price target raised to $85 from $80 at Canaccord
08/19/20 Roth Capital
Turning Point Therapeutics price target raised to $77 from $75 at Roth Capital
07/13/20 Roth Capital
Roth Capital positive on Turning Point Therapeutics appointment of Partridge
TPTX Turning Point Therapeutics
$102.72 /

+0.82 (+0.80%)

  • 19
    May
Upgrade
Check Point upgraded to Neutral from Sell at Goldman Sachs » 19:45
10/25/20
10/25
19:45
10/25/20
19:45
CHKP

Check Point

$120.41 /

-0.54 (-0.45%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CHKP Check Point
$120.41 /

-0.54 (-0.45%)

CHKP Check Point
$120.41 /

-0.54 (-0.45%)

08/20/20
Fly Intel: Top five analyst initiationsNewPage
08/20/20 Deutsche Bank
Check Point initiated with a Hold at Deutsche Bank
07/23/20 Wedbush
Check Point price target raised to $140 from $125 at Wedbush
07/23/20 Credit Suisse
Check Point price target raised to $125 from $110 at Credit Suisse
CHKP Check Point
$120.41 /

-0.54 (-0.45%)

CHKP Check Point
$120.41 /

-0.54 (-0.45%)

CHKP Check Point
$120.41 /

-0.54 (-0.45%)

Periodicals
Blackstone to buy Simply Self storage for $1.2B, WSJ reports » 17:47
10/25/20
10/25
17:47
10/25/20
17:47
BX

Blackstone

$54.59 /

-0.17 (-0.31%)

, BAM

Brookfield

$33.89 /

+0.025 (+0.07%)

Blackstone (BX) has…

Blackstone (BX) has struck a deal to buy Simply Self Storage from Brookfield Asset Management (BAM), The Wall Street Journal's Miriam Gottfried reports. The private-equity company's nontraded real-estate investment trust, known as BREIT, is buying the 8M square-foot portfolio of self-storage facilities for about $1.2B. The deal is expected to be announced Monday, the author adds. Reference Link

ShowHide Related Items >><<
BX Blackstone
$54.59 /

-0.17 (-0.31%)

BAM Brookfield
$33.89 /

+0.025 (+0.07%)

BX Blackstone
$54.59 /

-0.17 (-0.31%)

06/25/20
Fly Intel: Top five analyst initiations
06/25/20 UBS
Blackstone initiated with a Buy at UBS
06/08/20 Citi
Citi downgrades Alternative Asset Managers to Market Weight, lowers four ratings
06/08/20 Citi
Blackstone downgraded to Neutral from Buy at Citi
BAM Brookfield
$33.89 /

+0.025 (+0.07%)

10/23/20 Credit Suisse
Athene could still bid for American Equity, faces 'hurdles,' says Credit Suisse
10/19/20
Fly Intel: Top five analyst upgrades
10/19/20 Citi
Brookfield upgraded to Buy from Neutral at Citi
09/23/20 JPMorgan
Brookfield shares remain undervalued, says JPMorgan
BX Blackstone
$54.59 /

-0.17 (-0.31%)

BAM Brookfield
$33.89 /

+0.025 (+0.07%)

BX Blackstone
$54.59 /

-0.17 (-0.31%)

BAM Brookfield
$33.89 /

+0.025 (+0.07%)

BX Blackstone
$54.59 /

-0.17 (-0.31%)

BAM Brookfield
$33.89 /

+0.025 (+0.07%)

BX Blackstone
$54.59 /

-0.17 (-0.31%)

Periodicals
Facebook preparing measures for possible election unrest, WSJ says » 17:43
10/25/20
10/25
17:43
10/25/20
17:43
FB

Facebook

$284.89 /

+6.78 (+2.44%)

Facebook teams have…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FB Facebook
$284.89 /

+6.78 (+2.44%)

FB Facebook
$284.89 /

+6.78 (+2.44%)

10/22/20 Argus
Snap price target raised to $50 from $30 at Argus
10/20/20 Jefferies
Facebook price target raised to $320 from $310 at Jefferies
10/20/20 Credit Suisse
Facebook price target raised to $322 from $315 at Credit Suisse
10/15/20 Cowen
Trump unhappiness may reinforce odds of antitrust action on Facebook, says Cowen
FB Facebook
$284.89 /

+6.78 (+2.44%)

FB Facebook
$284.89 /

+6.78 (+2.44%)

FB Facebook
$284.89 /

+6.78 (+2.44%)

FB Facebook
$284.89 /

+6.78 (+2.44%)

Periodicals
Apple Services business could be hit in Google antitrust battle, WSJ reports » 17:38
10/25/20
10/25
17:38
10/25/20
17:38
GOOG

Alphabet

$1,640.50 /

+25.89 (+1.60%)

, GOOGL

Alphabet Class A

$1,632.77 /

+24.75 (+1.54%)

, AAPL

Apple

$115.05 /

-0.77 (-0.66%)

The Justice…

The Justice Department's attempt to punish Google (GOOG) for its competitive practices in internet search could end up taking a major toll on a different tech giant: Apple (AAPL), The Wall Street Journal's Tim Higgins reports. A multibillion-dollar deal in which Google pays to be the default search engine on Apple's iPhones and other devices is at the heart of the case the U.S. government filed last week against Google. That deal is also at the heart of Apple's services unit, which has been the biggest contributor to its growth over the past several years, the author notes. The government has pointed to the deal, whose history dates back 15 years, as an example of how Google, a unit of Alphabet, uses its giant profits to block out competition-a contention Google denies.Reference Link

ShowHide Related Items >><<
GOOGL Alphabet Class A
$1,632.77 /

+24.75 (+1.54%)

GOOG Alphabet
$1,640.50 /

+25.89 (+1.60%)

AAPL Apple
$115.05 /

-0.77 (-0.66%)

GOOG Alphabet
$1,640.50 /

+25.89 (+1.60%)

10/23/20 Cleveland Research
Alphabet upgraded to Buy on Search, Cloud momentum at Cleveland Research
10/22/20 Jefferies
Jefferies says 71% of Google users would still use search if removed from device
10/21/20 JPMorgan
Alphabet arguments against lawsuit have merits, says JPMorgan
10/21/20 Morgan Stanley
Slack downgraded to Underweight on rising competitive risk at Morgan Stanley
GOOGL Alphabet Class A
$1,632.77 /

+24.75 (+1.54%)

10/23/20 Cleveland Research
Alphabet Class A upgraded to Buy from Neutral at Cleveland Research
AAPL Apple
$115.05 /

-0.77 (-0.66%)

10/22/20 Cleveland Research
Cleveland Research sees further upside for Apple iPhone forecasts
10/22/20 DA Davidson
Apple 'looks good to us', says DA Davidson
10/22/20 Morgan Stanley
Apple iPhone12 cycle early data points trending positively, says Morgan Stanley
10/22/20 Piper Sandler
Apple price target raised to $135 from $130 at Piper Sandler
GOOG Alphabet
$1,640.50 /

+25.89 (+1.60%)

AAPL Apple
$115.05 /

-0.77 (-0.66%)

GOOG Alphabet
$1,640.50 /

+25.89 (+1.60%)

AAPL Apple
$115.05 /

-0.77 (-0.66%)

GOOG Alphabet
$1,640.50 /

+25.89 (+1.60%)

AAPL Apple
$115.05 /

-0.77 (-0.66%)

GOOGL Alphabet Class A
$1,632.77 /

+24.75 (+1.54%)

AAPL Apple
$115.05 /

-0.77 (-0.66%)

GOOGL Alphabet Class A
$1,632.77 /

+24.75 (+1.54%)

AAPL Apple
$115.05 /

-0.77 (-0.66%)

Hot Stocks
Coca-Cola European Partners announces proposed acquisition of Coca-Cola Amatil » 17:19
10/25/20
10/25
17:19
10/25/20
17:19
CCEP

Coca-Cola European Partners

$39.00 /

-0.485 (-1.23%)

, CCLAY

Coca-Cola Amatil

$0.00 /

+ (+0.00%)

, KO

Coca-Cola

$50.52 /

-0.15 (-0.30%)

Coca-Cola European…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
KO Coca-Cola
$50.52 /

-0.15 (-0.30%)

CCEP Coca-Cola European Partners
$39.00 /

-0.485 (-1.23%)

CCEP Coca-Cola European Partners
$39.00 /

-0.485 (-1.23%)

07/06/20 ABN Amro
Coca-Cola European Partners upgraded to Buy from Hold at ABN Amro
06/22/20 Citi
Citi calls Coca-Cola European Partners its Top Pick in Beverages
06/10/20 ABN Amro
Coca-Cola European Partners upgraded to Hold from Sell at ABN Amro
06/05/20 HSBC
Coca-Cola European Partners initiated with a Hold at HSBC
CCLAY Coca-Cola Amatil
$0.00 /

+ (+0.00%)

10/21/20 JPMorgan
Coca-Cola Amatil upgraded to Overweight from Neutral at JPMorgan
08/06/20 Goldman Sachs
Coca-Cola Amatil upgraded to Buy from Neutral at Goldman Sachs
05/26/20 Goldman Sachs
Coca-Cola Amatil upgraded to Neutral from Sell at Goldman Sachs
05/26/20 Goldman Sachs
Coca-Cola Amatil upgraded to Neutral from Sell at Goldman Sachs
KO Coca-Cola
$50.52 /

-0.15 (-0.30%)

10/23/20 Morgan Stanley
Coca-Cola price target raised to $57 from $54 at Morgan Stanley
10/20/20 Jefferies
National Beverage upgraded to Hold on better La Croix market share at Jefferies
10/12/20 Citi
PepsiCo upgraded to Buy from Neutral at Citi
09/28/20 Morgan Stanley
PepsiCo trading at good entry point ahead of earnings, says Morgan Stanley
KO Coca-Cola
$50.52 /

-0.15 (-0.30%)

KO Coca-Cola
$50.52 /

-0.15 (-0.30%)

CCEP Coca-Cola European Partners
$39.00 /

-0.485 (-1.23%)

KO Coca-Cola
$50.52 /

-0.15 (-0.30%)

KO Coca-Cola
$50.52 /

-0.15 (-0.30%)

Periodicals
Amazon wins order to stall $3.4B Reliance-Future deal, Bloomberg says » 17:12
10/25/20
10/25
17:12
10/25/20
17:12
AMZN

Amazon.com

$3,203.69 /

+28.72 (+0.90%)

Amazon.com secured relief…

Amazon.com secured relief in its dispute with Future Group after a court put a temporary hold on Future's $3.4B sale deal with Reliance Industries, Bloomberg's Upmanyu Trivedi and P R Sanjai report. An arbitration court in Singapore restrained Future Retail and its founders from going ahead with the sale of assets, according to people with knowledge of the matter. The ruling was on Amazon's request for an interim order before main tribunal hearings start, the authors note. Reference Link

ShowHide Related Items >><<
AMZN Amazon.com
$3,203.69 /

+28.72 (+0.90%)

AMZN Amazon.com
$3,203.69 /

+28.72 (+0.90%)

10/20/20 Citi
Citi likes Amazon head of Q3 results despite Prime Day language
10/19/20 Piper Sandler
Amazon Prime Day sales up 49% year-over-year, says Piper Sandler
10/16/20 Citi
Citi questions if Amazon's Prime Day may disappoint compared to last year
10/15/20 Truist
Truist says indications show Amazon Prime Day again a 'record sales period'
AMZN Amazon.com
$3,203.69 /

+28.72 (+0.90%)

AMZN Amazon.com
$3,203.69 /

+28.72 (+0.90%)

AMZN Amazon.com
$3,203.69 /

+28.72 (+0.90%)

AMZN Amazon.com
$3,203.69 /

+28.72 (+0.90%)

AMZN Amazon.com
$3,203.69 /

+28.72 (+0.90%)

Periodicals
Carlyle nearing $2.4B deal for Siemen's Flender business, Bloomberg says » 17:09
10/25/20
10/25
17:09
10/25/20
17:09
CG

Carlyle Group

$27.50 /

-0.2 (-0.72%)

, SIEGY

Siemens

$0.00 /

+ (+0.00%)

Carlyle Group (CG) is…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SIEGY Siemens
$0.00 /

+ (+0.00%)

CG Carlyle Group
$27.50 /

-0.2 (-0.72%)

CG Carlyle Group
$27.50 /

-0.2 (-0.72%)

10/13/20 Citi
Carlyle Group upgraded to Buy from Neutral at Citi
06/08/20 Citi
Citi downgrades Alternative Asset Managers to Market Weight, lowers four ratings
06/08/20 Citi
Carlyle Group downgraded to Neutral from Buy at Citi
04/15/20
Fly Intel: Top five analyst upgrades
SIEGY Siemens
$0.00 /

+ (+0.00%)

10/09/20 JPMorgan
Siemens Q4 numbers not likely an important catalyst, says JPMorgan
10/06/20 Vertical Research
Siemens upgraded to Buy from Hold at Vertical Research
10/02/20 UBS
Siemens price target lowered to EUR 122 from EUR 134 at UBS
09/29/20 Deutsche Bank
Siemens price target lowered to EUR 123 from EUR 135 at Deutsche Bank
SIEGY Siemens
$0.00 /

+ (+0.00%)

CG Carlyle Group
$27.50 /

-0.2 (-0.72%)

SIEGY Siemens
$0.00 /

+ (+0.00%)

CG Carlyle Group
$27.50 /

-0.2 (-0.72%)

SIEGY Siemens
$0.00 /

+ (+0.00%)

CG Carlyle Group
$27.50 /

-0.2 (-0.72%)

Periodicals
Dunkin' Brands near deal for $9B sale to Inspire Brands, NYTimes reports » 17:06
10/25/20
10/25
17:06
10/25/20
17:06
DNKN

Dunkin' Brands

$88.70 /

-0.5 (-0.56%)

Dunkin' Brands, the…

Dunkin' Brands, the parent company of the Dunkin' and Baskin Robbins chains, is in talks to sell itself to a private equity-backed company, Inspire Brands, the New York Times's Lauren Hirsch reported earlier. The deal being discussed, which could be announced as soon as Monday, would take Dunkin' Brands private at a price of $106.50 a share, said two people with knowledge of the negotiations. The company has since confirmed that it has held preliminary discussions to be acquired by Inspire Brands. Reference Link

ShowHide Related Items >><<
DNKN Dunkin' Brands
$88.70 /

-0.5 (-0.56%)

DNKN Dunkin' Brands
$88.70 /

-0.5 (-0.56%)

10/23/20 KeyBanc
Dunkin' Brands price target raised to $97 from $78 at KeyBanc
10/20/20 Cleveland Research
Dunkin' Brands U.S. comps look to have improved, says Cleveland Research
10/19/20 Wells Fargo
Dunkin' Brands price target raised to $83 from $67 at Wells Fargo
10/06/20 Piper Sandler
Piper teen survey shows Snap, Amazon and Apple remain favorites
DNKN Dunkin' Brands
$88.70 /

-0.5 (-0.56%)

DNKN Dunkin' Brands
$88.70 /

-0.5 (-0.56%)

DNKN Dunkin' Brands
$88.70 /

-0.5 (-0.56%)

Hot Stocks
Dunkin' Brands confirms preliminary discussions to be acquired by Inspire Brands » 16:51
10/25/20
10/25
16:51
10/25/20
16:51
DNKN

Dunkin' Brands

$88.70 /

-0.5 (-0.56%)

Dunkin' Brands, the…

Dunkin' Brands, the parent company of Dunkin' and Baskin-Robbins, confirms that it has held preliminary discussions to be acquired by Inspire Brands. There is no certainty that any agreement will be reached. The company said it will not comment further unless and until a transaction is agreed or discussions are terminated.

ShowHide Related Items >><<
DNKN Dunkin' Brands
$88.70 /

-0.5 (-0.56%)

DNKN Dunkin' Brands
$88.70 /

-0.5 (-0.56%)

10/23/20 KeyBanc
Dunkin' Brands price target raised to $97 from $78 at KeyBanc
10/20/20 Cleveland Research
Dunkin' Brands U.S. comps look to have improved, says Cleveland Research
10/19/20 Wells Fargo
Dunkin' Brands price target raised to $83 from $67 at Wells Fargo
10/06/20 Piper Sandler
Piper teen survey shows Snap, Amazon and Apple remain favorites
DNKN Dunkin' Brands
$88.70 /

-0.5 (-0.56%)

DNKN Dunkin' Brands
$88.70 /

-0.5 (-0.56%)

DNKN Dunkin' Brands
$88.70 /

-0.5 (-0.56%)

Recommendations
China Tesla car recall seems 'a pretty big deal,' says GLJ Research » 16:29
10/25/20
10/25
16:29
10/25/20
16:29
TSLA

Tesla

$420.61 /

-5.22 (-1.23%)

Commenting on the…

Commenting on the reported 50K China Tesla car recall, GLJ Research analyst Gordon Johnson says he thinks "the entire China initiative for TSLA is falling apart." The analyst argues that Elon Musk made promises "it seems he will not be able to keep to the Chinese government." "What's important about the recall isn't its impressive size, it's that it is happening at all," Johnson adds, noting that it is "a 100% elective action by China." The analyst believes this "is a big deal," and likely why despite $6B more in cash in Q3 versus Q2, Tesla's interest income was down 25% quarter-over-quarter.

ShowHide Related Items >><<
TSLA Tesla
$420.61 /

-5.22 (-1.23%)

TSLA Tesla
$420.61 /

-5.22 (-1.23%)

10/23/20 Morgan Stanley
Tesla price target raised to $360 from $333 at Morgan Stanley
10/22/20
Fly Intel: Top five analyst upgrades
10/22/20 GLJ Research
GLJ keeps $40 target on Tesla, says business model not sustainable
10/22/20 RBC Capital
Tesla price target raised to $339 from $290 at RBC Capital
TSLA Tesla
$420.61 /

-5.22 (-1.23%)

  • 14
    Feb
TSLA Tesla
$420.61 /

-5.22 (-1.23%)

TSLA Tesla
$420.61 /

-5.22 (-1.23%)

TSLA Tesla
$420.61 /

-5.22 (-1.23%)

Earnings
SAP lowers FY20 revenue guidance to EUR 27.2-EUR 27.8B, from EUR 27.8B-EUR 28.5B » 16:21
10/25/20
10/25
16:21
10/25/20
16:21
SAP

SAP

$149.68 /

+2.15 (+1.46%)

SAP said in a statement…

SAP said in a statement that, "While SAP continues to see robust interest in its solutions to drive digital transformation as customers look to emerge from the crisis with more resilience and agility, lockdowns have been recently re-introduced in some regions and demand recovery has been more muted than expected. Further and for the same reasons, SAP no longer anticipates a meaningful recovery in SAP Concur business travel-related revenues for the remainder of the year 2020." SAP continues to expect its share of more predictable revenue to be approximately 72%. The company has also raised its cash flow expectations for 2020 on the back of a strong year-to-date cash flow performance and now expects an operating cash flow of approximately EUR 6.0B - previously above EUR 5.0B - and a free cash flow above EUR 4.5B - previously approximately EUR 4.0B. Additionally, SAP said that, "The acceleration of customers' move to the cloud and subsequent business transformations which drive the new ambition's cloud revenue target of more than EUR 22B by 2025. SAP expects this to negatively impact the 2023 operating margin by approximately 4 to 5 percentage points relative to the previous mid-term ambition."

ShowHide Related Items >><<
SAP SAP
$149.68 /

+2.15 (+1.46%)

SAP SAP
$149.68 /

+2.15 (+1.46%)

10/08/20 JPMorgan
SAP expected to give Qualtrics update with Q3 results, says JPMorgan
07/28/20 JPMorgan
SAP price target raised to EUR 160 from EUR 125 at JPMorgan
07/28/20 Credit Suisse
SAP price target raised to EUR 157 from EUR 135 at Credit Suisse
07/28/20 BMO Capital
SAP price target raised to $170 from $130 at BMO Capital
SAP SAP
$149.68 /

+2.15 (+1.46%)

SAP SAP
$149.68 /

+2.15 (+1.46%)

SAP SAP
$149.68 /

+2.15 (+1.46%)

Earnings
Celanese expects FY20 adjusted EPS of $7-$7.10, consensus $6.99 » 16:16
10/25/20
10/25
16:16
10/25/20
16:16
CE

Celanese

$120.09 /

+2.065 (+1.75%)

"Across most of our…

"Across most of our end markets, global demand during the third quarter progressed well along the path of recovery," said Lori Ryerkerk, Celanese's chairman and chief executive officer. "We are monitoring the current resurgence of COVID-19 across various locations for any impact to our businesses. At this stage, the October and November order books are shaping consistently with the third quarter and show no indications of demand retraction. We expect continued momentum in the fourth quarter to partially offset various sequential headwinds including normal December seasonality and a major turnaround at our Frankfurt POM facility. Including all these factors, we expect full year 2020 adjusted earnings of approximately $7.00 to $7.10 per share. Looking to 2021, we remain confident that underlying demand will reach pre-COVID levels at some point in the year. While uncertainty remains, we continue to be focused on controllable actions to drive strong growth next year, including productivity, production planning, and disciplined capital deployment."

ShowHide Related Items >><<
CE Celanese
$120.09 /

+2.065 (+1.75%)

CE Celanese
$120.09 /

+2.065 (+1.75%)

10/19/20 Truist
Truist raises price targets in select Chemicals names
10/07/20 KeyBanc
Celanese upgraded to Overweight from Sector Weight at KeyBanc
10/07/20 KeyBanc
Celanese upgraded to Overweight from Sector Weight at KeyBanc
09/21/20 Evercore ISI
Celanese initiated with an Outperform at Evercore ISI
CE Celanese
$120.09 /

+2.065 (+1.75%)

CE Celanese
$120.09 /

+2.065 (+1.75%)

Earnings
Celanese reports Q3 adjusted EPS $1.95, consensus $1.70 » 16:14
10/25/20
10/25
16:14
10/25/20
16:14
CE

Celanese

$120.09 /

+2.065 (+1.75%)

Reports Q3 revenue $1.4B,…

Reports Q3 revenue $1.4B, consensus $1.34B. "Our financial results are again a reflection of the commitment of our employees to the success of Celanese in any environment. They have taken decisive actions throughout this year to respond to the difficult realities of COVID-19 and continue to navigate persistent challenges to better serve and support our customers each day. With the recovery we have seen to date, I am pleased to share that all of our production facilities across the globe are again fully staffed and operating to meet demand. We continue to closely monitor business conditions and will remain nimble and purposeful in preparing ourselves for continued recovery and growth in the future. We are encouraged by robust demand recovery for our products across all regions in the third quarter," said Lori Ryerkerk, chairman and chief executive officer.

ShowHide Related Items >><<
CE Celanese
$120.09 /

+2.065 (+1.75%)

CE Celanese
$120.09 /

+2.065 (+1.75%)

10/19/20 Truist
Truist raises price targets in select Chemicals names
10/07/20 KeyBanc
Celanese upgraded to Overweight from Sector Weight at KeyBanc
10/07/20 KeyBanc
Celanese upgraded to Overweight from Sector Weight at KeyBanc
09/21/20 Evercore ISI
Celanese initiated with an Outperform at Evercore ISI
CE Celanese
$120.09 /

+2.065 (+1.75%)

CE Celanese
$120.09 /

+2.065 (+1.75%)

Hot Stocks
Mirati reports preliminary results from mutant KRAS selective inhibitor programs » 16:10
10/25/20
10/25
16:10
10/25/20
16:10
MRTX

Mirati Therapeutics

$180.37 /

+0.13 (+0.07%)

Mirati Therapeutics…

Mirati Therapeutics announced preliminary results from the company's mutant KRAS selective inhibitor programs. The preliminary results included updated clinical data of adagrasib, the company's KRAS G12C inhibitor, presented at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Therapeutics and initial preclinical in vivo data of MRTX1133, the company's selective and potent potential first-in-class KRAS G12D inhibitor. In a pooled assessment of 110 patients harboring a G12C mutation in NSCLC, CRC and other solid tumors, monotherapy adagrasib has been well tolerated. 4.5% of treatment-related adverse events led to discontinuation. Over 50 patients have been treated with adagrasib in combination with either pembrolizumab in NSCLC, cetuximab in CRC and TNO-155 in NSCLC or CRC. Each combination has been well tolerated. The pembrolizumab and cetuximab combination cohorts are ongoing and each have cleared the dose limiting toxicity evaluation period at the full dose of each commercial agent and at a 600 mg BID dose of adagrasib. The TNO-155 combination dose escalation and expansion cohorts are ongoing at a 600 mg BID dose of adagrasib. Regarding preliminary efficacy data as of August 30, 2020 in patients with advanced NSCLC treated with adagrasib as a monotherapy at a 600 mg BID dose: Patients had a median of two prior systemic treatments, including all patients receiving prior treatment with platinum-based chemotherapy regimens and 92% of patients receiving prior treatment with an anti-PD-1 /L1 inhibitor. 4 of 6 responders have a duration of treatment for greater than 11 months and all 4 patients remain on treatment. Preliminary explorative correlative analysis of co-mutations of KRAS G12C and STK11 in advanced NSCLC showed a 64% ORR across pooled Phase 1/1b and Phase 2 cohorts. Approximately 30% of all KRAS G12C mutant NSCLC patients have a STK11 co-occurring mutation. Co-occurring KRAS and STK11 mutations have been shown to be significantly correlated with poor clinical outcomes when treated with immunotherapy and platinum-based chemotherapy regimens. In a case study presented from the ongoing clinical trial of adagrasib as a monotherapy, a heavily pre-treated NSCLC patient with an unirradiated, active brain metastases observed a 67% reduction in tumor volume including the disappearance of a metastatic brain lesion. Preclinical studies demonstrate dose-dependent brain and cerebrospinal fluid exposure. The Phase 2 cohort of adagrasib as a monotherapy is currently enrolling additional NSCLC patients with active brain metastases to further explore this patient population which has a high unmet medical need. In a case study presented from the ongoing clinical trial of adagrasib in combination with TNO-155 in collaboration with Novartis, a heavily pre-treated NSCLC patient treated in the combination trial of adagrasib and TNO-155 observed a 60% reduction in tumor volume.

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$180.37 /

+0.13 (+0.07%)

MRTX Mirati Therapeutics
$180.37 /

+0.13 (+0.07%)

10/21/20 BMO Capital
Mirati Therapeutics price target raised to $176 from $101 at BMO Capital
10/08/20 Credit Suisse
Mirati Therapeutics price target raised to $190 from $140 at Credit Suisse
09/28/20 BofA
Mirati Therapeutics initiated with a Neutral at BofA
09/28/20 BofA
Mirati Therapeutics initiated with a Neutral at BofA
MRTX Mirati Therapeutics
$180.37 /

+0.13 (+0.07%)

  • 10
    Jan
Hot Stocks
Cenovus Energy, Husky Energy combine to create oil, natural gas company » 16:02
10/25/20
10/25
16:02
10/25/20
16:02
CVE

Cenovus Energy

$3.72 /

-0.03 (-0.80%)

Cenovus Energy and Husky…

Cenovus Energy and Husky Energy announced "a transaction to create a new integrated Canadian oil and natural gas company with an advantaged upstream and downstream portfolio that is expected to provide enhanced free funds flow generation and superior return opportunities for investors." The companies have entered into a definitive arrangement agreement under which Cenovus and Husky will combine in an all-stock transaction valued at $23.6B, inclusive of debt. The combined company will operate as Cenovus Energy Inc. and remain headquartered in Calgary, Alberta. The transaction has been unanimously approved by the Boards of Directors of Cenovus and Husky and is expected to close in the first quarter of 2021. The combination has low exposure to Alberta oil pricing while maintaining exposure to global commodity prices. The combined company will be the third largest Canadian oil and natural gas producer, based on total company production, with about 750,000 barrels of oil equivalent per day of low-cost oil and natural gas production, including 50,000 BOE/d of high free funds flow generating offshore Asia Pacific production. It will be the second largest Canadian-based refiner and upgrader, with total North American upgrading and refining capacity of approximately 660,000 barrels per day, which includes approximately 350,000 bbls/d of heavy oil conversion capacity. The company will have access to about 265,000 bbls/d of current takeaway capacity out of Alberta on existing major pipelines, as well as about 305,000 bbls/d of committed capacity on planned pipelines. In addition, it will have 16 million barrels of crude oil storage capacity as well as strategic crude-by-rail assets that provide takeaway optionality. The combined company is expected to generate an incremental $1.2B of annual free funds flow, comprised of $600 million in annual corporate and operating synergies and $600M in annual capital allocation synergies, achievable independent of commodity prices. The vast majority of the annual savings are anticipated to be achieved in the first year of combined operations, with the full amount of the annual run rate synergies realized within year two. The companies anticipate additional future savings based on opportunities for further physical integration of the upstream and downstream heavy oil assets. The anticipated $600M in annual corporate and operating cost synergies will be achieved through reductions to combined workforce and corporate overhead costs including streamlined IT systems and procurement savings through economies of scale. The company is expected to sustain production levels and downstream operations with an anticipated annual capital investment of $2.4B, a reduction of more than $600M per year compared with what would be required by the two companies on a standalone basis. The combined company is expected to be free funds flow breakeven in 2021 at WTI prices of US$36/bbl, with a line of sight to reducing its free funds flow breakeven to less than WTI US$33/bbl by 2023. This is lower than either company on a standalone basis. At closing, the combined company is expected to have ample liquidity with $8.5B in undrawn committed credit facilities and no bond maturities until 2022.

ShowHide Related Items >><<
CVE Cenovus Energy
$3.72 /

-0.03 (-0.80%)

CVE Cenovus Energy
$3.72 /

-0.03 (-0.80%)

10/20/20 Morgan Stanley
Cenovus Energy price target lowered to C$6 from C$8 at Morgan Stanley
10/16/20 National Bank
Cenovus Energy price target lowered to C$8 from C$11 at National Bank
10/01/20
Fly Intel: Top five analyst downgrades
10/01/20 JPMorgan
Cenovus downgraded to Underweight on valuation, leverage at JPMorgan
CVE Cenovus Energy
$3.72 /

-0.03 (-0.80%)

CVE Cenovus Energy
$3.72 /

-0.03 (-0.80%)

Hot Stocks
Essa Pharma presents therapeutics potential of EPI-7386 » 15:55
10/25/20
10/25
15:55
10/25/20
15:55
EPIX

Essa Pharma

$6.20 /

-0.26 (-4.02%)

Essa Pharma presented new…

Essa Pharma presented new preclinical data on ESSA's clinical candidate, EPI-7386, at the 32nd EORTC-NCI-AACR Annual Symposium on Molecular Targets and Cancer Therapeutics. In an in vitro cellular thermal shift assay, EPI-7386 was shown to physically interact with the both the full-length and the splice variant form of the androgen receptor. In an in vitro full-length AR-driven cellular model, RNAseq data was analyzed by pathway enrichment analysis. EPI-7386 demonstrates largely similar modulation of AR-regulated genes compared to enzalutamide, but with additional unique elements. EPI-7386 exhibits superior activity to enzalutamide in the AR-V7-driven cellular models LNCaP95 and 22Rv1 by modulating AR-driven gene expression with or without the addition of an external androgen.

ShowHide Related Items >><<
EPIX Essa Pharma
$6.20 /

-0.26 (-4.02%)

  • 29
    Jul
Hot Stocks
Lianluo Smart Limited, Newegg announce entering into merger agreement » 15:52
10/25/20
10/25
15:52
10/25/20
15:52
LLIT

Lianluo Smart Limited

$0.41 /

-0.0593 (-12.75%)

Lianluo Smart Limited and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LLIT Lianluo Smart Limited
$0.41 /

-0.0593 (-12.75%)

Hot Stocks
Turning Point Therapeutics presents initial data from Phase 1 SHIELD-1 study » 15:46
10/25/20
10/25
15:46
10/25/20
15:46
TPTX

Turning Point Therapeutics

$102.72 /

+0.82 (+0.80%)

Turning Point…

Turning Point Therapeutics reported initial clinical data from the ongoing Phase 1 dose finding portion of its SHIELD-1 study of drug candidate, TPX-0022, a potent inhibitor of MET and the associated cancer signaling pathways of SRC and CSF1R. The initial data highlighted preliminary clinical activity, including objective responses across multiple tumor types and a generally tolerable safety profile. Twenty-two patients were treated across four dose levels from Sept. 2019 to the data cut-off date of Oct. 15, 2020. Patients included those with MET-altered non-small cell lung cancer, colorectal cancer, gastric or gastroesophageal junction cancer and glioblastoma. The median number of prior therapies was three, with all patients having received at least one prior line of chemotherapy and/or immunotherapy and the majority of patients having received multiple rounds of prior combination chemotherapy. Sixty-eight percent of patients had a baseline ECOG performance score of 1. Preliminary efficacy data was available for 15 evaluable patients with baseline measurable disease and at least one post-baseline scan. TPX-0022 was generally well tolerated, with the most frequent treatment emergent adverse event being Grade 1 or 2 dizziness. Of 10 MET TKI-naive patients, five achieved a partial response, including three with GC or GEJ cancer, one with CRC, and one with NSCLC. All three evaluable patients with gastric or GEJ tumors achieved a response. Of the five responses, three patients achieved a confirmed response, and two patients remained on treatment in a response awaiting confirmation at the time of the data cut-off. Of the five MET TKI-pretreated NSCLC patients, three patients treated with multiple rounds of prior therapy achieved a best response of stable disease with two patients showing tumor measurement improvements. Nine of 15 patients achieved clinical benefit. Six of 15 patients remained on treatment with duration of treatment ranging from 7.6+ to 34+ weeks. The company anticipates initiating Phase 1 dose expansion after determining the recommended Phase 2 dose. Turning Point plans to discuss the ongoing Phase 1 SHIELD-1 study with the Food and Drug Administration to potentially modify the trial into a registrational Phase 1/2 design. The company is targeting initiation of the Phase 2 portion in the second half of 2021, pending FDA feedback. In parallel, based on the SHIELD-1 study initial findings, a combination study with TPX-0022 and an epidermal growth factor receptor tyrosine kinase inhibitor in patients with EGFR mutated MET-amplified NSCLC is also planned for initiation in the second half of 2021. In addition, preclinical data for the company's lead drug candidate repotrectinib were reported in two poster presentations. The first poster expanded on previous work presented in June at AACR 2020 with additional preclinical data of repotrectinib in combination with the KRAS-G12C inhibitor, AMG-510, in a NSCLC xenograft tumor model. In preclinical studies, repotrectinib significantly enhanced efficacy of AMG-510 and showed a marked survival benefit in a KRAS G12C xenograft model when compared to AMG-510 alone. Repotrectinib previously showed synergy in preclinical models with AMG-510 and inhibited KRAS G12C tumor cell proliferation, suppressed receptor tyrosine kinase upregulation induced by AMG-510, and reduced KRAS G12C tumor cell cytokine release. Similar results have since been obtained with other KRAS G12C inhibitors. With the new results presented in a KRAS G12C xenograft tumor model, and previous data shown with repotrectinib in combination with a MEK inhibitor, the company now plans to initiate a clinical combination study in KRAS mutant NSCLC in mid-2021. Further details on the design will be shared at the time of study initiation. The second poster showed preclinical studies of repotrectinib as monotherapy and in combination with irinotecan and temozolomide in neuroblastoma cell lines and pediatric patient-derived xenograft models. Repotrectinib combined with chemotherapy demonstrated increased anti-tumor activity compared to chemotherapy alone in an ALK-mutant neuroblastoma PDX model.

ShowHide Related Items >><<
TPTX Turning Point Therapeutics
$102.72 /

+0.82 (+0.80%)

TPTX Turning Point Therapeutics
$102.72 /

+0.82 (+0.80%)

09/21/20 H.C. Wainwright
Turning Point price target raised to $100 from $88 at H.C. Wainwright
08/21/20 Canaccord
Turning Point Therapeutics price target raised to $85 from $80 at Canaccord
08/19/20 Roth Capital
Turning Point Therapeutics price target raised to $77 from $75 at Roth Capital
07/13/20 Roth Capital
Roth Capital positive on Turning Point Therapeutics appointment of Partridge
TPTX Turning Point Therapeutics
$102.72 /

+0.82 (+0.80%)

  • 19
    May
Hot Stocks
Revolution Medicines reports progress, expansion of combo strategy with RMC-4630 » 15:39
10/25/20
10/25
15:39
10/25/20
15:39
RVMD

Revolution Medicines

$40.39 /

+1.17 (+2.98%)

, AZN

AstraZeneca

$52.01 /

+0.03 (+0.06%)

Revolution Medicines…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RVMD Revolution Medicines
$40.39 /

+1.17 (+2.98%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

RVMD Revolution Medicines
$40.39 /

+1.17 (+2.98%)

09/14/20 Jefferies
Inhibrx initiated with a Buy at Jefferies
05/21/20
Fly Intel: Top five analyst initiations
05/21/20 H.C. Wainwright
Revolution Medicines initiated with a Buy at H.C. Wainwright
03/09/20
Fly Intel: Top five analyst initiations
AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
10/08/20 JPMorgan
AstraZeneca FY20 guide could look conservative after Q3 results, says JPMorgan
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
09/29/20 Berenberg
AstraZeneca initiated with a Buy at Berenberg
RVMD Revolution Medicines
$40.39 /

+1.17 (+2.98%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

  • 09
    Jul
  • 13
    Feb
AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

RVMD Revolution Medicines
$40.39 /

+1.17 (+2.98%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

Hot Stocks
Syros presents initial data from Phase 1 trial of SY-5609 » 15:34
10/25/20
10/25
15:34
10/25/20
15:34
SYRS

Syros Pharmaceuticals

$7.55 /

+0.135 (+1.82%)

Syros Pharmaceuticals…

Syros Pharmaceuticals announced initial safety, pharmacokinetics and pharmacodynamics data from the ongoing dose-escalation portion of its Phase 1 clinical trial of SY-5609 in patients with select solid tumors. SY-5609 is a highly selective and potent oral cyclin-dependent kinase 7 inhibitor. These early data demonstrate proof of mechanism in patients with advanced solid tumors and establish a maximum tolerated dose for continuous daily dosing. The data was presented in a poster session at the 32nd EORTC-NCI-AACR Symposium. The study also includes a cohort evaluating SY-5609 in combination with fulvestrant in CDK4/6 inhibitor-resistant HR-positive breast cancer patients. As of August 21, 17 patients had been enrolled in the trial and were eligible for safety, PK and PD analysis. Patients were either treated with continuous daily dosing of single-agent SY-5609 at 1, 3, 4 or 5 mg, or for three weeks on and one week off at 3 mg in combination with fulvestrant. The median age of the patients enrolled in the study was 64. Patients were heavily pretreated with a median of four prior therapies. The MTD for continuous daily dosing was achieved at 3 mg. The data showed that SY-5609 demonstrated dose-dependent increases in POLR2A mRNA expression, a PD marker being used in the trial to measure CDK7 biological activity. Notably, increases in POLR2A in patients treated at 3 mg daily reached levels associated with tumor regressions in preclinical models, as well as with levels of CDK7 target engagement at which a clinical response and apoptosis were observed in a trial of patients treated with a first-generation IV CDK7 inhibitor. SY-5609 demonstrated approximately dose-proportional PK as both a single agent and in combination, minimal accumulation with repeat dosing, and a steady state half-life compatible with once-daily dosing. The majority of adverse events reported with SY-5609 as a single agent were low grade. The most common AEs were nausea, diarrhea, fatigue, platelet count decrease, and vomiting. The safety profile of SY-5609 in combination with fulvestrant was consistent with that of single-agent SY-5609. Five of the 13 patients treated with single-agent SY-5609 were response evaluable, and of those, three achieved stable disease and two had progressive disease; one of the four patients treated in the combination cohort was response evaluable and had progressive disease. The Phase 1 trial continues to actively enroll patients with select solid tumors, including the recently expanded single-agent cohort in lung cancer patients and combination cohort in breast cancer patients, to further evaluate the 3 mg daily dose in focused patient populations. The trial has also been opened to patients with advanced pancreatic cancer, another tumor type that has demonstrated sensitivity to SY-5609 in preclinical models. Additional cohorts are evaluating alternate regimens, supported by preclinical data showing that intermittent regimens of SY-5609 induced tumor regressions. Syros expects to report additional dose-escalation data, including clinical activity data, in mid-2021.

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$7.55 /

+0.135 (+1.82%)

SYRS Syros Pharmaceuticals
$7.55 /

+0.135 (+1.82%)

09/22/20 Alliance Global Partners
Syros Pharmaceuticals initiated with a Buy at Alliance Global Partners
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
08/06/20 JMP Securities
Syros Pharmaceuticals price target raised to $20 from $16 at JMP Securities
08/06/20 Piper Sandler
Syros Pharmaceuticals price target raised to $18 from $14 at Piper Sandler
SYRS Syros Pharmaceuticals
$7.55 /

+0.135 (+1.82%)

Hot Stocks
Aileron announces proof-of-concept data from ALRN-6924 Phase 1b trial » 15:31
10/25/20
10/25
15:31
10/25/20
15:31
ALRN

Aileron Therapeutics

$1.92 /

-0.19 (-9.00%)

Aileron Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ALRN Aileron Therapeutics
$1.92 /

-0.19 (-9.00%)

ALRN Aileron Therapeutics
$1.92 /

-0.19 (-9.00%)

06/05/20 H.C. Wainwright
Aileron Therapeutics price target lowered to $2 from $3 at H.C. Wainwright
05/27/20 JonesTrading
JonesTrading sees potential positive myelopreservation data in June for Aileron
04/08/20 JonesTrading
Aileron Therapeutics initiated with a Buy at JonesTrading
04/08/20 JonesTrading
Aileron Therapeutics initiated with a Buy at JonesTrading
ALRN Aileron Therapeutics
$1.92 /

-0.19 (-9.00%)

  • 04
    Jun
Hot Stocks
Momo announces Yan Tang as Executive Chairman, Li Wang as new CEO » 15:13
10/25/20
10/25
15:13
10/25/20
15:13
MOMO

Momo

$15.22 /

+0.56 (+3.82%)

Momo announced that its…

Momo announced that its board of directors has approved Yan Tang to step down from the position of Chief Executive Officer, and promoted Li Wang to this position, effective on November 1, 2020. Wang is a director of the Company, currently serving as the President and Chief Operating Officer of Momo. Starting from November 1, 2020, Yan Tang will become the executive chairman of the board of directors of Momo, in which role he will continue to be integrally involved in setting the strategic priorities and directing new business initiatives for Momo.

ShowHide Related Items >><<
MOMO Momo
$15.22 /

+0.56 (+3.82%)

09/04/20
Fly Intel: Top five analyst initiations
09/04/20
Fly Intel: Top five analyst downgrades
09/04/20 86 Research
Momo initiated with a Buy at 86 Research
09/04/20 Morgan Stanley
Momo downgraded to Equal Weight on core business risk at Morgan Stanley
MOMO Momo
$15.22 /

+0.56 (+3.82%)

MOMO Momo
$15.22 /

+0.56 (+3.82%)

MOMO Momo
$15.22 /

+0.56 (+3.82%)

Conference/Events
RenovaCare to host conference call » 12:31
10/25/20
10/25
12:31
10/25/20
12:31
RCAR

RenovaCare

$0.00 /

+ (+0.00%)

Management holds a…

Management holds a conference call to provide an overview of the Company's performance in 2020 year-to-date and also discuss its business objectives for 2021 on October 29 at 11 am. Webcast Link

ShowHide Related Items >><<
RCAR RenovaCare
$0.00 /

+ (+0.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.